On February 19, 2021 Cyclacel Pharmaceuticals, Inc. (the "Company") and Judy Chiao, MD entered into a
retirement agreement (the "Retirement Agreement"), effective on the eighth day following the date of the
Retirement Agreement. Pursuant to the Retirement Agreement, Dr. Chiao's employment with the Company shall
terminate as of March 5, 2021 (the "Separation Date"). The Retirement Agreement contains the entire agreement
of the parties and supersedes all prior agreements between the parties related to Dr. Chiao's employment with
the Company.
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.